The articles listed here are updated regularly and address cutting-edge research addressing the unique immunology found in the liver. 

A next-generation treatment for bile duct cancer

Tinengotinib has a unique binding mechanism away from the ATP binding pocket that enables it to target even newly resistant cancer cells. It overcomes acquired resistance by targeting FGFR2 kinase domain mutations. Essentially, by inhibiting a number of different...

read more